NEWSROOM

Healthcare

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Apr 5, 2024

Pittsburgh, PA, April 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel...

PRISM MarketView Features Auto Parts 4 Less in the Automotive E-Commerce Marketplace

PRISM MarketView Features Auto Parts 4 Less in the Automotive E-Commerce Marketplace

Apr 5, 2024

New York, N.Y., April 05, 2024 - PRISM MarketView announces the release of an informative interview with Auto Parts 4 Less CEO Christopher Davenport, explaining the company’s strategic business model and focus on expanding its automotive eCommerce marketplace. Christopher Davenport - CEO of Auto Parts 4 Less Auto Parts 4 Less is an innovator focused on developing a world-class eCommerce marketplace for automotive parts that utilizes integrated technologies to optimize the listing, selling, and...

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

Apr 3, 2024

Pittsburgh, PA, April 03, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for the evaluation of LP-10, an intravesical liposomal formulation of tacrolimus, as a potential treatment for...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

Apr 2, 2024

BioStem CEO, Jason Matuszewski, will present on Tuesday, April 9, 2024, at 12:30 pm ET POMPANO BEACH, FLORIDA, April 2, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will present at the 14th Annual LD Micro Invitational Conference at the Sofitel New York on April 8-9, 2024. BioStem’s Chief Executive Officer, Jason...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase

Apr 1, 2024

-Project Continued Growth from Sales of AmnioWrap2®- -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, FLORIDA, April 1, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the fourth quarter and twelve months ended December 31, 2023. Jason Matuszewski, CEO of BioStem,...

American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results

American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results

Mar 27, 2024

- Acquisition of 3 Rhode Island Radiation Therapy Cancer Centers progressing toward closing- - International Cancer Center equipment upgrade completed in Ecuador, Opening new Puebla, Mexico Center in Q2- - Lease extensions signed at 4 of 10 Gamma Knife customer sites – -Sales Pipeline continues to advance- -Conference Call Thursday, March 28th at 12:00 pm ET / 9:00 am PT - SAN FRANCISCO, CA, March 27, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company") a leading...

American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results

American Shared Hospital Services Pays Tribute to Ernest A. Bates, M.D., Founder and Former Chairman and CEO

Mar 26, 2024

Dr. Bates, Pioneering Neurosurgeon and Philanthropist, passed on March 19, 2024 SAN FRANCISCO, CA, March 26, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that Company Founder, former Chairman and Chief Executive Officer, and Board Director, Ernest A. Bates, M.D, passed away on Tuesday, March 19th at the age of...

PRISM MARKETVIEW PREVIEWS ANTICIPATED FDA DRUG APPROVALS FOR 2024

Mar 25, 2024

New York, N.Y., March 25, 2024 - PRISM MarketView - Drug development is an arduous, costly and time-consuming process for the teams involved behind the scenes, and the patients anxiously awaiting breakthroughs in different disease areas. It takes 12 years on average for a company to take a drug from discovery to commercialization, and every hard-won FDA approval is a cause for celebration for researchers, companies and the end-users whose lives may be changed by these treatments. The past few...

American Shared Hospital Services Announces Fourth Quarter 2023 Earnings Conference Call

American Shared Hospital Services Announces Fourth Quarter 2023 Earnings Conference Call

Mar 22, 2024

Conference Call on Thursday, March 28th at 12:00 pm ET / 9:00 am PT SAN FRANCISCO, CA, March 22, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its fourth quarter 2023 financial results on Thursday, March 28th at 12:00 pm ET / 9:00 am PT. The fourth quarter...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024

Mar 21, 2024

Conference Call on Monday, April 1st, at 4:30 pm ET POMPANO BEACH, FLORIDA, March 21, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its fourth quarter 2023 financial results post-market Monday, April 01, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Monday, April 01, 2024....

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

Mar 18, 2024

New York, N.Y., March 18, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™ and the companies leading the charge in developing new, safe, and effective treatments for liver disease. The landmark decision has shone a light on metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic fatty liver disease, a leading cause of liver-related mortality that affects between...

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

Mar 12, 2024

The first Mitral Valve Replacement using the Made in India SSi Mantra Surgical Robotic System was successfully performed at the Narayana Institute of Cardiac Sciences in Bengaluru, India FORT LAUDERDALE, FL, March 12, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII) ), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced that surgeons...

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

Mar 7, 2024

New York, N.Y., March 07, 2024 - PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory accomplishments and how investors stand to benefit. Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease (GvHD) and previously received Orphan Drug Designation for LP-10 in 2023. With these nods from the...

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

Mar 5, 2024

Clinical testing of LP-410 expected to commence in Q2 2024 Pittsburgh, PA, March 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GVHD). Lipella’s...

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

Feb 29, 2024

New York, N.Y., February 29, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million Americans. All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders. Approximately 95% of rare...

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

Feb 26, 2024

New York, N.Y. February 26, 2024 - PRISM MarketView announces the release of an insightful interview with BioStem Technologies' (OTC: BSEM) CEO, Jason Matuszewski, discussing the company's strategic focus on revolutionizing the wound care market through innovative regenerative medicine solutions. BioStem Technologies, a frontrunner in regenerative medicine, is dedicated to leveraging the healing properties of placental-derived allografts to enhance wound care. The company stands out for its...

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Feb 20, 2024

Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company’s lead candidate, LP-10 Pittsburgh, PA, February 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference’s key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET....

PRISM MarketView Marks World Cancer Day

PRISM MarketView Marks World Cancer Day

Feb 1, 2024

New York, N.Y., February 01, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors. It is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, and is the second leading cause of death in the United States. To mark World Cancer Day, which will be held on February 4, PRISM MarketView...

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

SS Innovations Demonstrates Groundbreaking Telesurgery Platform at Company’s First Multi-Specialty Robotic Surgical Conference

Feb 1, 2024

Remote coronary artery suturing performed on animal model via SS Innovations’ telesurgery platform SMRSC 2024 welcomed global medical experts and innovators to explore the future of robotic surgery FORT LAUDERDALE, FL, February 01, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII) ), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, conducted a groundbreaking live...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies

Jan 30, 2024

BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for Amniowrap2™ effective January 1st in all 50 states and territories POMPANO BEACH, FLORIDA, January 30, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced...

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

SS Innovations Announces Filing of Pre-Submission Application to the Center for Devices and Radiological Health (CDRH) of the United States Food and Drug Administration

Jan 26, 2024

FORT LAUDERDALE, FL, January 26, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it has filed a pre-submission application with the U.S. Food and Drug Administration (FDA) requesting feedback on its SSi MantraTM Surgical Robotic System. SS Innovations received acknowledgement of this pre...

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

SS Innovations Partners with India’s Leading Medical Equipment Supplier, Medikabazaar

Jan 25, 2024

Collaboration to facilitate sales of the SSi Mantra Surgical Robotic System to hospitals and medical facilities across India FORT LAUDERDALE, FL, January 25, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced it has entered into a partnership with India’s leading medical equipment supplier,...

Remsleep Holdings Inc.’s DeltaWave Mask has received questions from FDA regarding 510k submission (K233415)

Remsleep Holdings Inc.’s DeltaWave Mask has received questions from FDA regarding 510k submission (K233415)

Jan 22, 2024

Tampa, FL, January 22, 2024 - RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) has received a response to the company’s 510(K) submission K233415. The agency has determined that additional information is required. The agency has asked for additional information regarding Administrative Information, Device Description, Substantial Equivalence (SE), Labeling, Biocompatibility, and...

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

SS Innovations Launches Groundbreaking Inaugural Multi-Specialty Robotic Surgical Conference

Jan 22, 2024

SMRSC 2024 brings global medical experts and technological innovators together to explore the future of robotic surgery 13 Live, broadcasted surgeries were performed by distinguished multi-specialty surgeons, using the SSi Mantra Surgical Robotic System Distinguished guests included the Honorable Governor of Haryana, Mr. Bandaru Dattatreya FORT LAUDERDALE, FL, January 22, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative...

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

Jan 16, 2024

IRVINE, CA, January 16, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/ About...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role

Jan 11, 2024

Mr. McCarrey brings a strong track record of success and deep experience in regenerative medicine markets POMPANO BEACH, FLORIDA, January 11, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer. BioStem Technologies CEO, Jason...

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

SS Innovations Achieves Significant Milestones in 2023

Jan 8, 2024

Company’s award winning SSi Mantra surgical robotic system has completed over 550 surgeries and is clinically validated to perform more than 40 different types of surgical procedures Company Builds Strong Foundation for Future Growth FORT LAUDERDALE, FL, January 8, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population,...

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Dec 28, 2023

New York, December 28, 2023 - Microbot Medical Inc. (Nasdaq: MBOT) has completed its GLP pivotal pre-clinical study for the LIBERTY® Endovascular Robotic Surgical System. The study, adhering to FDA guidelines and using a porcine model, successfully met all its objectives, including conducting 96 robotic navigations by three interventional radiologists. This involved evaluating target vessels and surrounding tissues with the LIBERTY system controlling various intravascular catheterization...

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

SS Innovations Announces Strategic Partnership with Surgical Lab for Distribution in Africa

Dec 26, 2023

Pan African Medical Device Distributor Surgical Lab to place the SSi Mantra Surgical Robotic System in Healthcare Facilities across the African Continent Surgical Lab has Begun Registration of SSi Mantra in 27 African countries FORT LAUDERDALE, FL, December 26, 2023 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population,...

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

Dec 20, 2023

-Lipella Granted Two Orphan Drug Designations by FDA- Pittsburgh, PA, December 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations...